Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Short-term Investments (2023 - 2025)

Compass Therapeutics' Short-term Investments history spans 3 years, with the latest figure at $178.3 million for Q4 2025.

  • For Q4 2025, Short-term Investments rose 114.16% year-over-year to $178.3 million; the TTM value through Dec 2025 reached $178.3 million, up 114.16%, while the annual FY2025 figure was $178.3 million, 114.16% up from the prior year.
  • Short-term Investments for Q4 2025 was $178.3 million at Compass Therapeutics, up from $173.7 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $178.3 million in Q4 2025 and bottomed at $71.6 million in Q1 2025.
  • The 3-year median for Short-term Investments is $130.4 million (2023), against an average of $125.2 million.
  • The largest YoY upside for Short-term Investments was 114.16% in 2025 against a maximum downside of 46.01% in 2025.
  • A 3-year view of Short-term Investments shows it stood at $128.2 million in 2023, then plummeted by 35.09% to $83.2 million in 2024, then surged by 114.16% to $178.3 million in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Short-term Investments are $178.3 million (Q4 2025), $173.7 million (Q3 2025), and $78.1 million (Q2 2025).